{"nctId":"NCT04531098","briefTitle":"A Bridging Study: Comparing Two Lots of Sci-B-Vac™ and Engerix-B in Healthy Adults","startDateStruct":{"date":"2006-03-02","type":"ACTUAL"},"conditions":["Hepatitis B"],"count":402,"armGroups":[{"label":"Sci-B-Vac-SciGen","type":"EXPERIMENTAL","interventionNames":["Biological: Sci-B-Vac-Lot B"]},{"label":"Engerix-B","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Engerix-B"]},{"label":"Sci-B-Vac-BTG","type":"EXPERIMENTAL","interventionNames":["Biological: Sci-B-Vac-Lot A"]}],"interventions":[{"name":"Sci-B-Vac-Lot B","otherNames":["Sci-B-Vac","3-antigen HepB Vaccine","Bio-Hep-B"]},{"name":"Sci-B-Vac-Lot A","otherNames":["Sci-B-Vac","3-antigen HepB Vaccine","Bio-Hep-B"]},{"name":"Engerix-B","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nHealthy adults 18 to 45 years of age who were seronegative for HBsAg, anti-HBs, anti-Hepatitis B core antigen, HIV, and Hepatitis C Virus (HCV)\n\nExclusion Criteria:\n\n* Evidence of alcoholism or drug abuse, history of HIV, or HCV\n* Blood transfusions within the three months prior to inclusion in the study\n* Uncontrolled hypertension and other cardiovascular diseases\n* Chronic/concurrent administration (\\>14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose. Inhaled and topical steroids were permitted\n* History of anaphylaxis (including shock) or any significant allergy or atopy","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"45 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With an Antibody Response (≥10 IU/Liter) to Hepatitis B Surface Antigens One Month After the Third Vaccination","description":"Percentage of participants with an antibody response to hepatitis B surface antigens (anti-HBs), defined as an anti-HBs titer ≥10 IU/liter, one month after the third vaccination (Day 210) in the According-to-Protocol (ATP) population.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"120","spread":null},{"groupId":"OG001","value":"115","spread":null},{"groupId":"OG002","value":"109","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With an Anti-HBs Antibody Titer ≥10 IU/Liter at Days 180, 210 and 360.","description":"Percentage of participants with an anti-HBs antibody response, defined as an anti-HBs titer ≥10 IU/liter, just prior to the third vaccination (Day 180) and 1 month (Day 210) and 6 months (Day 360) after the third vaccination in the According-to-Protocol (ATP) population.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"118","spread":null},{"groupId":"OG001","value":"95","spread":null},{"groupId":"OG002","value":"102","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"120","spread":null},{"groupId":"OG001","value":"115","spread":null},{"groupId":"OG002","value":"109","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"115","spread":null},{"groupId":"OG001","value":"110","spread":null},{"groupId":"OG002","value":"101","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-HBs Geometric Mean Concentration (GMC)","description":"Geometric mean concentration (GMC) of anti-HBs antibody just prior to the third vaccination (Day 180) and 1 month (Day 210) and 6 months (Day 360) after the third vaccination in the According-to-Protocol (ATP) population.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"328.64","spread":null},{"groupId":"OG001","value":"44.42","spread":null},{"groupId":"OG002","value":"147.30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12,158.94","spread":null},{"groupId":"OG001","value":"4,124.24","spread":null},{"groupId":"OG002","value":"3,587.30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3188.68","spread":null},{"groupId":"OG001","value":"991.07","spread":null},{"groupId":"OG002","value":"1239.82","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With an Anti-HBs Antibody Titer ≥100 IU/Liter at Days 180, 210 and 360.","description":"Percentage of participants with an anti-HBs antibody response, defined as an anti-HBs titer ≥100 IU/liter, just prior to the third vaccination (Day 180) and 1 month (Day 210) and 6 months (Day 360) after the third vaccination in the According-to-Protocol (ATP) population.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99","spread":null},{"groupId":"OG001","value":"40","spread":null},{"groupId":"OG002","value":"68","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"118","spread":null},{"groupId":"OG001","value":"113","spread":null},{"groupId":"OG002","value":"106","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"113","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"94","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":131},"commonTop":["Injection site pain","Myalgia","Fatigue","Malaise","Injection site pruritus"]}}}